S
Shanghai-Hong Kong Zhongke
A one-stop pre-clinical CRO established by a full-time entrepreneurial team of the core team
About Shanghai-Hong Kong Zhongke
Shanghai-Hong Kong Zhongke International Biotechnology Co., Ltd. (ZSHK Laboratories) operates as a preclinical contract research organization (CRO) servicing the biopharmaceutical industry. Founded in 2019, the company is headquartered in Hong Kong with its origins tracing back to the Safety Assessment and Research Center of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The core team possesses over two decades of experience in drug safety evaluation.
The company's business model is centered on providing a comprehensive, one-stop platform for preclinical research and development services to a global client base of pharmaceutical companies and R&D institutions. This service-based revenue model encompasses a suite of offerings critical for drug and medical device development. Key services include pharmacology and pharmacodynamics research, drug metabolism and pharmacokinetic (DMPK) studies, and comprehensive safety evaluations. By managing these essential preclinical stages, ZSHK enables its clients to advance their products through the regulatory pipeline.
ZSHK has established a significant operational footprint with independent laboratory facilities in strategic locations, including the Hong Kong Science Park, Pingshan District in Shenzhen, and the Suzhou Industrial Park in Jiangsu. This network of labs is complemented by a strategic focus on the supply chain for research models; the company has developed breeding and research bases for experimental canines and non-human primates in Hunan and Guangxi. The company has received multiple rounds of venture capital funding, including a Series B round in November 2022, to support its expansion.
The firm's service portfolio is extensive, covering early screening, pharmacodynamics, pharmacokinetics, and toxicity prediction. It offers specialized services such as histopathology research and laboratory testing and analysis. ZSHK also provides robust support platforms, including advanced IT and computerized systems designed for data security, a comprehensive instrument management system compliant with international regulations (NMPA, OECD, FDA), and a sophisticated document management system to support multinational applications. A subsidiary, AnLing Biomed (Shenzhen) Co., Ltd., achieved GLP certification from the NMPA in April 2023, a key milestone indicating adherence to quality standards for non-clinical laboratory studies.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Nov 2022 | $14M | $55M | Ascendum Capital · AstraZeneca Pharmaceutical | ↗ |
Growth signals
Latest recorded traffic for Shanghai-Hong Kong Zhongke is 710 monthly website visits, up 20.3% over the last three months. Shanghai-Hong Kong Zhongke's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai-Hong Kong Zhongke in its local ecosystem
The Shanghai-Hong Kong Zhongke office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Ascendum Capital
AstraZeneca Pharmaceutical
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai-Hong Kong Zhongke on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai-Hong Kong Zhongke’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








